ADVANTAGENE, INC
Aglatimagene besadenovec (AdV-tk), an oncolytic adenovirus for local delivery combined with prodrug (Gene Mediated Cytotoxic Immunotherapy, GMCI), administered with chemoradiation for pancreatic cance
- Sector
- Biotech
- Headquarters
- AUBURNDALE, MA
- Latest Form D
- $28.7M, Nov 2018
- Total capital
- $39.6M
- Federal grants
- $3.6M
- 5 awards · 2015–2021
- Rank in peer group#246 of 479
- Private capital raised
- $35.9M
- 3 Form D · last Nov 2018
- 95 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611K
- Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611K
- Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$116K
- Private capital raisedForm D · SEC · 3rd filing$28.7M
- Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$2M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Federal grantHealth and Human S · Phase II · Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$300K
- Private capital raisedForm D · SEC · 1st filing$2.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3391 | CERo Therapeutics, Inc. | — | $44.6M |
| 3392 | Forte Biosciences | — | $44.1M |
| 3393 | Oncotelic Therapeutics, Inc. | — | $40.3M |
| 3394 | ADVANTAGENE, INC | — | $35.9M |
| 3395 | Allarity Therapeutics, Inc. | — | $26.9M |
| 3396 | OTHRAM, INC. | — | $31.7M |
| 3397 | Lakewood-Amedex, Inc. | — | $30M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Laura AguilarExecutive Officer
- Estuardo Aguilar-CordovaDirector · Executive Officer
- Edward BenzDirector
- Mitchell FinerDirector
- Paul ManningDirector
- Chris MartellDirector
- Glenn MattesDirector
- Udi MeravDirector
Show all 12 people
- Fred MermelsteinDirector
- Stephen RocamboliExecutive Officer
- Alan SmithDirector
- Sean StalfortDirector
Patents
- Methods Of Treating TIM-3 Elevationapplication
- Gmci And Ddri Combination Therapy For Treating Cancerapplication
- Methods Of Treating TIM-3 Elevationapplication
- Methods Of Treating TIM-3 Elevationapplication
- A Mixed Complementary Viral Vector For Gene Therapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.